Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NYSE:ATNM NASDAQ:ICCC NASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.54+2.7%$1.04$0.61▼$5.94$21.93M0.0820.71 million shs2.55 million shsATNMActinium Pharmaceuticals$1.78+2.3%$1.62$1.03▼$2.41$55.53M-0.53405,691 shs144,405 shsICCCImmuCell$6.40+4.6%$6.46$3.34▼$7.60$55.36M0.39,085 shs6,952 shsKPTIKaryopharm Therapeutics$7.11-7.4%$4.81$3.51▼$16.95$66.60M0.28214,607 shs132,469 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+2.67%+63.03%+41.28%+82.25%-67.09%ATNMActinium Pharmaceuticals+2.30%+2.30%+13.38%+15.58%-6.32%ICCCImmuCell+4.58%+5.09%-0.93%+0.95%+68.42%KPTIKaryopharm Therapeutics-7.42%+12.86%+75.56%+65.35%-39.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics2.9006 of 5 stars3.55.00.00.03.00.00.6ATNMActinium Pharmaceuticals2.3658 of 5 stars3.55.00.00.01.10.00.6ICCCImmuCell1.2885 of 5 stars0.05.00.00.02.30.01.3KPTIKaryopharm Therapeutics4.0121 of 5 stars3.40.00.04.63.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 3.00Buy$9.00484.42% UpsideATNMActinium Pharmaceuticals 3.00Buy$4.50152.81% UpsideICCCImmuCell 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00378.20% UpsideCurrent Analyst Ratings BreakdownLatest ALLR, ICCC, KPTI, and ATNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$42.00 ➝ $25.007/28/2025ALLRAllarity TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$0.83 per shareN/AATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AICCCImmuCell$26.49M2.19$0.07 per share95.18$3.30 per share1.94KPTIKaryopharm Therapeutics$145.24M0.42N/AN/A($27.55) per share-0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AICCCImmuCell-$2.16M$0.1933.69∞N/A6.23%6.25%3.87%11/12/2025 (Estimated)KPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)Latest ALLR, ICCC, KPTI, and ATNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025ALLRAllarity Therapeutics-$0.21-$0.15+$0.06-$0.15N/AN/A8/14/2025Q2 2025ICCCImmuCellN/A$0.06N/A$0.06N/A$6.45 million8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.312.31ATNMActinium PharmaceuticalsN/A10.2510.25ICCCImmuCell0.283.851.99KPTIKaryopharm TherapeuticsN/A0.990.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%ATNMActinium Pharmaceuticals27.50%ICCCImmuCell13.47%KPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%ATNMActinium Pharmaceuticals6.00%ICCCImmuCell5.60%KPTIKaryopharm Therapeutics2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1014.62 million14.61 millionNot OptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableICCCImmuCell709.05 million8.54 millionNot OptionableKPTIKaryopharm Therapeutics3808.67 million8.41 millionOptionableALLR, ICCC, KPTI, and ATNM HeadlinesRecent News About These Companies139,646 Shares in Karyopharm Therapeutics Inc. $KPTI Acquired by T. Rowe Price Investment Management Inc.August 28 at 4:51 AM | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 23, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of "Moderate Buy" by BrokeragesAugust 21, 2025 | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comKaryopharm’s Earnings Call: Clinical Wins Amid Financial StrainAugust 13, 2025 | msn.comKaryopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 12, 2025 | finanznachrichten.deKaryopharm Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | chron.comKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comKaryopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 11, 2025 | prnewswire.comKaryopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comEarnings Outlook For Karyopharm TherapeuticsAugust 8, 2025 | benzinga.comKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 29, 2025 | zacks.comJPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.July 22, 2025 | gurufocus.comHC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI)July 16, 2025 | msn.comKaryopharm stock tumbles after disclosing failed financing talksJuly 11, 2025 | investing.comKaryopharm lays off more workers as hunt for strategic alternatives turns up shortJuly 11, 2025 | fiercebiotech.comFKaryopharm Shares Slide After Financing Efforts Stall, Strategic Review UnderwayJuly 11, 2025 | msn.comKaryopharm to Cut About 20% of Workforce Amid Ongoing ReviewJuly 11, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, ICCC, KPTI, and ATNM Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.54 +0.04 (+2.67%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.52 -0.02 (-0.97%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Actinium Pharmaceuticals NYSE:ATNM$1.78 +0.04 (+2.30%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 08/29/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.ImmuCell NASDAQ:ICCC$6.40 +0.28 (+4.58%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.50 +0.11 (+1.64%) As of 08/29/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Karyopharm Therapeutics NASDAQ:KPTI$7.11 -0.57 (-7.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.09 -0.02 (-0.34%) As of 08/29/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
